AUGS PFD Week 2018 - Call for Submissions

Welcome to the PFD Week 2018 abstract submission system! Here you can submit a late breaking abstract for the PFD Week 2018. Please carefully read all instructions below. Information regarding registration is now available on the PFD Week 2018 Website.

Begin a Submission

Important Notes

Abstract Submissions

Workshop Submissions

Roundtable Submissions

Detailed Instructions for Submission Types

  1. Oral and Poster Abstracts

    ELIGILIBILTY
    Who Is Eligible to Submit?
    AUGS Members and non-members are eligible to submit an abstract.

    Work submitted for presentation at this meeting may not have been previously published, and may not have been previously presented at another national Obstetrics and Gynecology (SGS, ACOG, AAGL) or Urology (SUFU, AUA) meeting. Please do not submit case reports as they are not permitted and will not be reviewed. Abstracts that have been presented at non-OBGYN or Urology meetings will be accepted for poster presentation only and will not be eligible for prizes. The author must list where and when the research was presented at the bottom of the abstract when submitted. It is acceptable, however, for it to have been presented at an international meeting outside the United States.

    Institutional Review Board Waiver
    The Institutional Review Board is charged with protecting the rights and welfare of people involved in research. IRB approval or waiver is required for submission of all abstracts. You will be required during online submission to document whether your study has been IRB reviewed. You will be asked to enter the unique IRB identifier number in the space provided on the web form. If approval is waived by an IRB, AUGS must receive a copy of the waiver letter by the submission deadline.

    The deadline for electronic submissions for abstracts is April 20, 2020 at 11:59 PM, ET.

    SUBMISSION CRITERIA
    The following are the guidelines for all oral, poster, or video abstract submissions:

    Abstract Character Limit
    • Title character limit: None
    • Body character limit: There is a limit of 3300 (including spaces) characters for the text of your submission. You will be advised of your character count usage throughout the submission process as you save and move to the next step.
    • Figures and Tables limit: You may add up to 2 figures and/or tables to your submission. Figures and tables will appear at the end of your abstract, both on the proof and for publication. Figures and tables cannot be placed within the text of the submission. Tables must be converted to an image and uploaded as a jpg, png, or gif file. Tables and figures will count as 560 characters towards your abstract character count.

    Abstract Title
    • Please make sure you double-check your title, as it will be published as submitted.
    • Use mixed case for title – do not use all caps or all lowercase. Do not put your title in quotation marks.
    • Titles do not have a character limit.
    • Do not include trial group name in title of abstract.

    Authors
    • Please consult with your co-authors on how they would like their names to appear. Please enter all authors in the order they should appear in the heading of the abstract. If you (the Contact Author) are not the Presenter on a submission, you will need to provide contact information on the Presenter.
    • Relevant financial relationship(s) must be disclosed for ALL AUTHORS at the time of submission. If you do not have disclosure information for any co-authors, you will be allowed the opportunity to send them an email to complete their disclosure. All disclosures MUST be collected by the April 20th abstract deadline.

    Responsibilities of the Presenting Author
    The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract.

    The presenting author is responsible for the following:
    • Ensuring that all authors have read the abstract and agreed to be co-authors.
    • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by AUGS.
    • Obtaining all the conflict of interest disclosures.

    Abstract Body
    Omit all names and geographical references in the body of the abstract. Organize content in sections as follows:
    • Objective: describes the research objective
    • Methods: describes research methodology used
    • Results: summarizes evaluation, including outcome data
    • Conclusions: states the conclusions drawn from results

    Disclosure
    Disclose any 'relevant' financial relationships in accordance with the ACCME guidelines. The ACCME defines 'relevant' financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. List any financial interests, assistance, or relationships with companies, supporters, or commercial products related to the research (for example, ownership or partnership; research support; research grants; sponsors; stockholders, etc.). All listed authors/co-authors must have a completed disclosure within the online abstract management system.

    Presentation Type and Category
    • You will be asked to select the appropriate presentation type for your submission.
    • Some submission types will have only one selection from which to choose.
    • Select the appropriate category using the drop-down menus provided.

    PRODUCT NAME USAGE
    • For purposes of blind scoring, institutional names must be omitted whenever possible in the title and body of the abstract.
    • Authors are requested to avoid the use of commercially branded names.
    • If a specific device is only identifiable by its trade name, then this should appear in brackets after a generic description of the device.
    • Should it be necessary to use a trade name, then the trade names of all similar products or those within a class must be used.

    REVISIONS
    • Carefully check the proof of your abstract. Make sure all special characters and formatting are displaying properly in your proof.
    • If you find errors, return to the appropriate step by clicking on the step name in the left-hand menu to make your corrections.
    • You may return to the online submission site to revise your abstract until April 20, 2020 at 11:59 PM, ET.
    • After this date/time, the submission site will close, and no additional changes/edits can be made.
    • If your abstract contains errors, you may opt to withdraw the abstract.
    • If you have not completed all required sections and details, you will not be able to submit.
    • When all required information is entered, the "Submit" button will appear at the bottom of the "Confirmation" page.

    WITHDRAWALS
    • After April 20, presenting authors may submit a request to have an abstract withdrawn.
    • To withdraw a submitted abstract, written notification must be sent to nicole@augs.org.
    • This notification must include the title, authors and affiliations (as submitted), the control number, and the name, affiliation, phone, fax and e-mail of the submitter.
    • We recommend using the "View Submission" page as part of this notification.

    NEED HELP?
    • For technical assistance, regarding the abstract submission site, contact The Conference Exchange technical support at 401-334-0220 between 8:30 AM and 6:00 PM, ET, Monday through Friday, or seven days a week using the feedback form.
    • For general abstract inquiries, email nicole@augs.org.

    ABSTRACT REVIEW
    • After the submission site closes, completed abstracts will be peer reviewed.
    • All abstracts will be blinded for review, meaning the abstracts will be reviewed without knowledge of the author/s, institution/s or disclosure information.
    • Accepted abstracts will be selected as oral, oral poster or poster

    ABSTRACT ACCEPTANCE/REJECTION NOTIFICATIONS
    • You will be notified electronically of the acceptance/rejection of your abstract June 12, 2020.
    • This notification will include the date and time of session/presentation as well as type of presentation if accepted.
    • Only the presenting author will be notified. It is the responsibility of the presenting author to notify all co-authors.
    • If you do not receive your notification by June 12, you should contact nicole@augs.org.

  2. Late-Breaking Abstract

    DEADLINE:
    The deadline for electronis submissions for late breaking abstracts is August 19, 2020 at 11:59 PM ET.

    Late-breaking abstract submissions are intended to allow for the timely presentation of high impact trials to AUGS meeting attendees. It is expected that these abstract submissions are from studies for which no preliminary data was available at the time of the abstract submission deadline (April 20, 2020).

    This meeting feature is not a mechanism to update previously submitted preliminary data or to provide an opportunity for previously rejected abstracts to be revised and resubmitted for consideration.

    Priority will be given (in the following order) to:
    • Results of phase III clinical trials
    • Results of phases II clinical trials
    • Extraordinary findings from a basic science investigation
    • Interim analyses of phase III trials that describe important secondary end points
    • Prospective multi-institution clinical trials

    The authors must fully describe all funding sources for their investigation.

    ABSTRACT CHARACTER LIMIT
    • Title character limit: None
    • Body character limit: There is a limit of 3300 (including spaces) characters for the text of your submission. You will be advised of your character count usage throughout the submission process as you save and move to the next step.
    • Figures and Tables limit: You may add up to 2 figures and/or tables to your submission. Figures and tables will appear at the end of your abstract, both on the proof and for publication. Figures and tables cannot be placed within the text of the submission. Tables must be converted to an image and uploaded as a jpg, png, or gif file. Tables and figures will count as 560 characters towards your abstract character count.

    ABSTRACT TITLE
    • Please make sure you double-check your title, as it will be published as submitted.
    • Use mixed case for title – do not use all caps or all lowercase. Do not put your title in quotation marks.
    • Titles do not have a character limit.
    • Do not include trial group name in title of abstract.

    AUTHORS
    • Please consult with your co-authors on how they would like their names to appear. Please enter all authors in the order they should appear in the heading of the abstract. If you (the Contact Author) are not the Presenter on a submission, you will need to provide contact information on the Presenter.
    • Relevant financial relationship(s) must be disclosed for ALL AUTHORS at the time of submission. If you do not have disclosure information for any co-authors, you will be allowed the opportunity to send them an email to complete their disclosure. All disclosures MUST be collected by the August 19 abstract deadline.

    RESPONSIBILITIES OF THE PRESENTING AUTHOR
    The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract.

    The presenting author is responsible for the following:
    • Ensuring that all authors have read the abstract and agreed to be co-authors.
    • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by AUGS.
    • Obtaining all the conflict of interest disclosures.

    ABSTRACT BODY
    Omit all names and geographical references in the body of the abstract. Organize content in sections as follows:
    • Objective: describes the research objective
    • Methods: describes research methodology used
    • Results: summarizes evaluation, including outcome data
    • Conclusions: states the conclusions drawn from results

    DISCLOSURE
    Disclose any 'relevant' financial relationships in accordance with the ACCME guidelines. The ACCME defines 'relevant' financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. List any financial interests, assistance, or relationships with companies, supporters, or commercial products related to the research (for example, ownership or partnership; research support; research grants; sponsors; stockholders, etc.). All listed authors/co-authors must have a completed disclosure within the online abstract management system.

    PRESENTATION TYPE AND CATEGORY
    • You will be asked to select the appropriate presentation type for your submission.
    • Some submission types will have only one selection from which to choose.
    • Select the appropriate category using the drop-down menus provided.

    PRODUCT NAME USAGE
    • For purposes of blind scoring, institutional names must be omitted whenever possible in the title and body of the abstract.
    • Authors are requested to avoid the use of commercially branded names.
    • If a specific device is only identifiable by its trade name, then this should appear in brackets after a generic description of the device.
    • Should it be necessary to use a trade name, then the trade names of all similar products or those within a class must be used.

    REVISIONS
    • Carefully check the proof of your abstract. Make sure all special characters and formatting are displaying properly in your proof.
    • If you find errors, return to the appropriate step by clicking on the step name in the left-hand menu to make your corrections.
    • You may return to the online submission site to revise your abstract until August 19, 2020 at 11:59 PM, ET.
    • After this date/time, the submission site will close, and no additional changes/edits can be made.
    • If your abstract contains errors, you may opt to withdraw the abstract.
    • If you have not completed all required sections and details, you will not be able to submit.
    • When all required information is entered, the "Submit" button will appear at the bottom of the "Confirmation" page.

    WITHDRAWALS
    • After August 31, presenting authors may submit a request to have an abstract withdrawn.
    • To withdraw a submitted abstract, written notification must be sent to nicole@augs.org.
    • This notification must include the title, authors and affiliations (as submitted), the control number, and the name, affiliation, phone, fax and e-mail of the submitter.
    • We recommend using the "View Submission" page as part of this notification.

    NEED HELP?
    • For technical assistance, regarding the abstract submission site, contact The Conference Exchange technical support at 401-334-0220 between 8:30 AM and 6:00 PM, ET, Monday through Friday, or seven days a week using the feedback form.
    • For general abstract inquiries, email nicole@augs.org.

    ABSTRACT REVIEW
    • After the submission site closes, completed abstracts will be peer reviewed.
    • All abstracts will be blinded for review, meaning the abstracts will be reviewed without knowledge of the author/s, institution/s or disclosure information.
    • Accepted abstracts will be selected as oral, oral poster or poster

  3. Tips & Tricks Submissions

    REQUIREMENTS
    Tips and tricks submissions have the same requirements as oral and poster abstracts, but you must also upload a video file.

    Videos and an accompanying abstract describing the objectives of the video must be submitted electronically through the website. The accompanying abstract must be written in English. It should contain a brief description of the Objectives, Methods and clinical relevance of the video submission maximum character is 3300, (same as abstract).

    If you are uploading a video abstract, please click on the "Upload Video" link on the left panel in order to upload your video.

    The below criteria must be met for acceptance of video presentation.
    • Maximum duration: 6 minutes
    • File cannot exceed 500 MB in size
    • Videos must have English captions or narration
    • Please ensure that your videos protect patient anonymity and integrity
    • Acceptable file formats are .mov, .mpg and mp4
    It is recommended that you edit your video for widescreen format (16:9 aspect ratio).

    PLEASE REMOVE ALL PRODUCT LOGOS/NAMES FROM VIDEO - if a video is submitted with the product name/logo included, the video will be disqualified from consideration

  4. Video Abstracts

    REQUIREMENTS
    Video abstracts have the same requirements as oral and poster abstracts, but you must also upload a video file.

    Videos and an accompanying abstract describing the objectives of the video must be submitted electronically through the website. The accompanying abstract must be written in English. It should contain a brief description of the Objectives, Methods and clinical relevance of the video submission maximum character is 3300, (same as abstract).

    If you are uploading a video abstract, please click on the "Upload Video" link on the left panel in order to upload your video.

    The below criteria must be met for acceptance of video presentation.
    • Maximum duration: 10 minutes
    • File cannot exceed 500 MB in size
    • Videos must have English captions or narration
    • Please ensure that your videos protect patient anonymity and integrity
    • Acceptable file formats are .mov, .mpg and mp4
    It is recommended that you edit your video for widescreen format (16:9 aspect ratio).

    PLEASE REMOVE ALL PRODUCT LOGOS/NAMES FROM VIDEO - if a video is submitted with the product name/logo included, the video will be disqualified from consideration

  5. Roundtables

    REQUIREMENTS
    All roundtable submitters must provide or answer the following:
    • Title of your roundtable
    • Intended audience: Physicians; Advanced Practice, Physical Therapy and Allied Health; Fellows; or Other
    • Level: Basic, Advanced, or All Levels
    • Have you presented this submission elsewhere? If yes, where?
    • Brief description/outline of roundtable: not to exceed 200 words
    • Aims & objectives: provide three aim/objectives completing the statement, "At the conclusion of this roundtable, participants will be able to..."
    • Keywords: provide between one and three keywords attendees can use to help find your roundtable
    • Facilitator: enter the name, contact information, and affiliation for the facilitator on the roundtable. Roundtables must have exactly one facilitator
    • Curriculum vitae: a CV must be submitted for the facilitator
    • CME Disclosure: the facilitator must disclose all financial relationships

    ROUNDTABLE ACCEPTANCE/REJECTION NOTIFICATIONS
    • You will be notified electronically of the acceptance/rejection of your roundtable March 27, 2020.
    • This notification will include the date and time of session/presentation as well as type of presentation if accepted.
    • Only the presenting author will be notified. It is the responsibility of the presenting author to notify all co-authors.
    • If you do not receive your notification by March 15, you should contact nicole@augs.org.

  6. Workshops

    REQUIREMENTS
    All workshop submitters must provide or answer the following:
    • Title of your workshop
    • Intended audience: Physicians; Advanced Practice, Physical Therapy and Allied Health; Fellows; or Other
    • Have you presented this submission elsewhere? If yes, where?
    • Workshop needs assessment
    • Materials needed
    • Proposed agenda
    • Learning objectives: provide between three and five objectives completing the statement, "At the conclusion of this workshop, participants will be able to..."
    • Keywords: provide between one and three keywords attendees can use to help find your workshop
    • Faculty: enter the name, contact information, and affiliation for the course director and faculty on the workshop. Workshops must have one course director and may have up to three additional faculty, for a total of four participants
    • CME Disclosure: the course director and all faculty must disclose all financial relationships
    WORKSHOP ACCEPTANCE/REJECTION NOTIFICATIONS
    • You will be notified electronically of the acceptance/rejection of your abstract March 27, 2020.
    • This notification will include the date and time of session/presentation as well as type of presentation if accepted.
    • Only the presenting author will be notified. It is the responsibility of the presenting author to notify all co-authors.
    • If you do not receive your notification by March 27, you should contact nicole@augs.org.